<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Europace</journal-id><journal-id journal-id-type="iso-abbrev">Europace</journal-id><journal-id journal-id-type="publisher-id">europace</journal-id><journal-id journal-id-type="hwp">europace</journal-id><journal-title-group><journal-title>Europace</journal-title></journal-title-group><issn pub-type="ppub">1099-5129</issn><issn pub-type="epub">1532-2092</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26559916</article-id><article-id pub-id-type="pmc">5072134</article-id><article-id pub-id-type="doi">10.1093/europace/euv344</article-id><article-id pub-id-type="publisher-id">euv344</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject><subj-group subj-group-type="heading"><subject>Cardiac Electrophysiology</subject></subj-group></subj-group></article-categories><title-group><article-title>Near zerO fluoroscopic exPosure during catheter ablAtion of supRavenTricular
arrhYthmias: the NO-PARTY multicentre randomized trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Casella</surname><given-names>Michela</given-names></name><!--<email>michelacasella@hotmail.com</email>--><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Dello Russo</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pelargonio</surname><given-names>Gemma</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Del Greco</surname><given-names>Maurizio</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Zingarini</surname><given-names>Gianluca</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Piacenti</surname><given-names>Marcello</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Di Cori</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Casula</surname><given-names>Victor</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Marini</surname><given-names>Massimiliano</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Pizzamiglio</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zucchetti</surname><given-names>Martina</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Riva</surname><given-names>Stefania</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Russo</surname><given-names>Eleonora</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Narducci</surname><given-names>Maria Lucia</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Soldati</surname><given-names>Ezio</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Panchetti</surname><given-names>Luca</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Startari</surname><given-names>Umberto</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Bencardino</surname><given-names>Gianluigi</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Perna</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Santangeli</surname><given-names>Pasquale</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Di Biase</surname><given-names>Luigi</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Cichocki</surname><given-names>Fabrizio</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fattore</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Bongiorni</surname><given-names>Mariagrazia</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Picano</surname><given-names>Eugenio</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Natale</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Tondo</surname><given-names>Claudio</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution>Cardiac Arrhythmia Research Centre, Centro Cardiologico Monzino,
IRCCS</institution>, <addr-line>Via Parea, 4</addr-line>,
<addr-line>20138</addr-line><addr-line>Milan</addr-line>, <country>Italy</country></aff><aff id="aff2">
<label>2</label>
<institution>Catholic University of the Sacred Heart</institution>,
<addr-line>Rome</addr-line>, <country>Italy</country></aff><aff id="aff3">
<label>3</label>
<institution>S. Chiara Hospital</institution>, <addr-line>Trento</addr-line>,
<country>Italy</country></aff><aff id="aff4">
<label>4</label>
<institution>Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di
Perugia</institution>, <addr-line>Perugia</addr-line>, <country>Italy</country></aff><aff id="aff5">
<label>5</label>
<institution>CNR, Institute of Clinical Physiology, Fondazione G. Monasterio</institution>,
<addr-line>Pisa</addr-line>, <country>Italy</country></aff><aff id="aff6">
<label>6</label>
<institution>University Hospital of Pisa</institution>, <addr-line>Pisa</addr-line>,
<country>Italy</country></aff><aff id="aff7">
<label>7</label>
<institution>Medical Research Center Oulu, Oulu University Hospital and University of
Oulu</institution>, <addr-line>Oulu</addr-line>, <country>Finland</country></aff><aff id="aff8">
<label>8</label>
<institution>University of Oulu</institution>, <addr-line>Oulu</addr-line>,
<country>Finland</country></aff><aff id="aff9">
<label>9</label>
<institution>Texas Cardiac Arrhythmia Institute at St Davis Medical Center</institution>,
<addr-line>Austin, TX</addr-line>, <country>USA</country></aff><aff id="aff10">
<label>10</label>
<institution>Universit&#x000e0; Bocconi</institution>, <addr-line>Milan</addr-line>,
<country>Italy</country></aff><aff id="aff11">
<label>11</label>
<institution>NU School of Medicine</institution>, <addr-line>Astana</addr-line>,
<country>Kazakhstan</country></aff><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Tel: +0039 02 58002340; fax: +0039 02 58002398.
<italic>E-mail address</italic>: <email>michelacasella@hotmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>10</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>11</month><year>2015</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>18</volume><issue>10</issue><fpage>1565</fpage><lpage>1572</lpage><history><date date-type="received"><day>4</day><month>6</month><year>2015</year></date><date date-type="accepted"><day>13</day><month>9</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; The Author 2015. Published by Oxford University Press on behalf of
the European Society of Cardiology.</copyright-statement><copyright-year>2015</copyright-year><license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits
non-commercial re-use, distribution, and reproduction in any medium, provided the
original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="euv344.pdf"/><abstract><title>Abstract</title><sec><title>Aims</title><p>Aim of this study was to compare a minimally fluoroscopic radiofrequency catheter
ablation with conventional fluoroscopy-guided ablation for supraventricular tachycardias
(SVTs) in terms of ionizing radiation exposure for patient and operator and to estimate
patients' lifetime attributable risks associated with such exposure.</p></sec><sec><title>Methods and results</title><p>We performed a prospective, multicentre, randomized controlled trial in six
electrophysiology (EP) laboratories in Italy. A total of 262 patients undergoing EP
studies for SVT were randomized to perform a minimally fluoroscopic approach (MFA)
procedure with the EnSite<sup>TM</sup>NavX<sup>TM</sup> navigation system or a
conventional approach (ConvA) procedure. The MFA was associated with a significant
reduction in patients' radiation dose (0 mSv, iqr 0&#x02013;0.08 vs. 8.87 mSv, iqr 3.67&#x02013;22.01;
<italic>P</italic> &#x0003c; 0.00001), total fluoroscopy time (0 s, iqr 0&#x02013;12 vs. 859 s, iqr
545&#x02013;1346; <italic>P</italic> &#x0003c; 0.00001), and operator radiation dose (1.55 vs. 25.33
&#x000b5;S per procedure; <italic>P</italic> &#x0003c; 0.001). In the MFA group, X-ray was not used
at all in 72% (96/134) of cases. The acute success and complication rates were not
different between the two groups (<italic>P</italic> = ns). The reduction in patients'
exposure shows a 96% reduction in the estimated risks of cancer incidence and mortality
and an important reduction in estimated years of life lost and years of life affected.
Based on economic considerations, the benefits of MFA for patients and professionals are
likely to justify its additional costs.</p></sec><sec><title>Conclusion</title><p>This is the first multicentre randomized trial showing that a MFA in the ablation of
SVTs dramatically reduces patients' exposure, risks of cancer incidence and mortality,
and years of life affected and lost, keeping safety and efficacy.</p></sec><sec><title>Trial registration</title><p>clinicaltrials.gov Identifier: NCT01132274.</p></sec></abstract><kwd-group><kwd>Supraventricular tachycardia</kwd><kwd>Radiofrequency ablation</kwd><kwd>Electroanatomical mapping</kwd><kwd>Radiation exposure</kwd></kwd-group></article-meta></front><body><boxed-text position="anchor" orientation="portrait"><caption><title>What's new?</title></caption><p>
<list list-type="bullet"><list-item><p>The radiation exposure during electrophysiology procedures is non-negligible for both
patients and laboratory staff.</p></list-item><list-item><p>The use of a minimally fluoroscopic approach (MFA) with the
EnSite<sup>TM</sup>NavX<sup>TM</sup> navigation system is associated with a
significant reduction in total fluoroscopy time, patients' exposure, and operator
radiation dose without any significant difference in terms of success and complication
rates. The reduction in patients' exposure shows a 96% reduction in the estimated
risks of cancer incidence and mortality and an important reduction in estimated years
of life lost and years of life affected.</p></list-item><list-item><p>The increase in life expectancy and in the period of cancer-free life makes the MFA
economically affordable at a rough economical analysis. Thus, faced with such an
advantage in terms of cancer prevention, it would be desirable that MFA procedures
were increasingly performed, at least in young patients.</p></list-item></list>
</p></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><p>Electrophysiology (EP) procedures are traditionally performed under fluoroscopic guidance
and often involve a non-negligible radiation exposure<sup><xref rid="EUV344C1" ref-type="bibr">1</xref>&#x02013;<xref rid="EUV344C4" ref-type="bibr">4</xref></sup> for both
patients and laboratory staff.</p><p>Fluoroscopy is certainly a highly effective way to navigate catheters and to monitor their
location; unfortunately, fluoroscopy requires the administration of ionizing radiation, and
recent epidemiological evidence shows that even low doses can be harmful and that no
completely safe dose exists.<sup><xref rid="EUV344C4" ref-type="bibr">4</xref></sup></p><p>In the past two decades, non-fluoroscopic three-dimensional (3D) mapping systems have been
used in complex arrhythmias ablation to guide the ablation strategy. More recently,
non-fluoroscopic 3D mapping systems have been broadly investigated for the complete or
near-complete abolishment of radiation exposure during ablation procedures, both in
paediatric patients<sup><xref rid="EUV344C5" ref-type="bibr">5</xref>&#x02013;<xref rid="EUV344C12" ref-type="bibr">12</xref></sup> and in adults,<sup><xref rid="EUV344C13" ref-type="bibr">13</xref>&#x02013;<xref rid="EUV344C21" ref-type="bibr">21</xref></sup> showing that catheter
ablation through a minimally fluoroscopic approach (MFA) is feasible and safe. However, most
of the data come from monocentric, non-randomized, feasibility studies. Therefore, it
remains unclear whether such an approach results in a clinically significant reduction in
exposure to ionizing radiation for both patient and operator.</p><p>The multicentre, randomized controlled NO-PARTY trial (<uri xlink:href="www.clinicaltrials.gov">www.clinicaltrials.gov</uri> identifier NCT01132274)
has been designed to compare a minimally fluoroscopic radiofrequency catheter ablation
(RFCA) guided by the EnSite<sup>TM</sup>NavX<sup>TM</sup> navigation system with
conventional fluoroscopy-guided RFCA for supraventricular tachycardias (SVTs) in terms of
ionizing radiation exposure for both patient and operator and to estimate patients' lifetime
attributable risks (LAR) associated with such exposure.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>An investigator-initiated, multicentre, randomized controlled trial was performed in six
Italian EP laboratories. Randomization of participants occurred between January 2010 and
February 2013; follow-up was completed in March 2014. The complete study protocol has been
previously described<sup><xref rid="EUV344C22" ref-type="bibr">22</xref></sup> (see <xref ref-type="supplementary-material" rid="sup1">Supplementary material online</xref>).
Written informed consent was obtained from all participants. The trial was approved by each
institutional review board.</p><p>Patients aged 14&#x02013;50 years undergoing SVTs RFCA were randomized on a 1 to 1 ratio to perform
an EP procedure with a MFA or conventional approach (ConvA). In case of a MFA procedure, the
EnSite<sup>TM</sup>NavX<sup>TM</sup> system was used as the primary catheter visualization
tool (<italic>Figure&#x000a0;<xref ref-type="fig" rid="EUV344F1">1</xref></italic>) and procedures
were performed only by MFA-skilled operators.<sup><xref rid="EUV344C23" ref-type="bibr">23</xref>&#x02013;<xref rid="EUV344C26" ref-type="bibr">26</xref></sup> Anyway, the use of
fluoroscopy was allowed in case the operator would have considered it necessary. <fig id="EUV344F1" orientation="portrait" position="float"><label>Figure&#x000a0;1</label><caption><p>(<italic>A</italic>) Non-fluoroscopic three-view reconstruction of the right atrium
in right anterior oblique (on the left) and in left anterior oblique (on the right)
views. The cloud of green points shows the sites reached by the mapping catheters and
used for geometry reconstruction. (<italic>B</italic>) The same geometry showing
catheter position inside the atrium: yellow catheter in coronary sinus, blue catheter
in Hisian region, and white ablation catheter mapping Koch triangle. The mapping
system allows to mark the areas of interest: in this case, we marked where ablation
pulses were safely and effectively delivered as shown in the intracavitary
electrograms recording box (bottom).</p></caption><graphic xlink:href="euv34401"/></fig></p><p>For both groups, fluoroscopic units were optimized at lower-exposure settings; in <xref ref-type="supplementary-material" rid="sup1">Supplementary material online, <italic>Table
S1</italic></xref>, characteristics of radiographic/fluoroscopic units are
described.</p><p>For all patients, total procedural time, time necessary to position catheters, EP study
time, and cumulative radiofrequency delivery time were collected.</p><p>Ionizing radiation use was calculated as total fluoroscopy time; patient's radiation
exposure was measured in terms of dose-area product (DAP), while operator exposure was
analysed with a specific kit of radiation dosimeters.</p><p>A follow-up outpatient visit was scheduled for each patient at 1, 3, 6, and 12 months to
take an updated history, perform physical examination, and obtain a 12-lead
electrocardiogram.</p><sec id="s2a"><title>Endpoints</title><p>The primary endpoint of the study was the reduction in the total radiation dose to the
patient. Secondary endpoints were procedural success, reduction in the procedural
fluoroscopy time, and reduction in the operator radiation dose. Moreover, an economic
assessment has been performed to evaluate the additional costs associated with a MFA
approach.</p></sec><sec id="s2b"><title>Radiation dose analysis</title><p>For each fluoroscopy, the interactions between the X-ray beam and the patient were
simulated via Monte Carlo calculation based on the geometry field of the procedure using
the validated software PCXMC version 2.0.<sup><xref rid="EUV344C27" ref-type="bibr">27</xref></sup> The X-ray spectra were reconstructed from the X-ray tube settings
(tube potential, anode angle, filtration) according to Birch and Marshall
theory,<sup><xref rid="EUV344C28" ref-type="bibr">28</xref></sup> and a modified
Cristy and Eckerman mathematical hermaphrodite phantom was used to represent a digital
phantom shaped on patient's height, weight, and age. Finally, measurements of DAP were
converted into organ doses, and effective doses (EDs) were estimated for each projection
using the ICRP 103 weighing factor. Effective dose was also calculated with the accepted
formula: mSv = DAP (Gy cm<sup>2</sup>) &#x000d7; 0.20 to better compare our data with others
published.<sup><xref rid="EUV344C29" ref-type="bibr">29</xref></sup></p><p>The risk of late effects induced by ionizing radiation exposure was assessed in terms of
LAR from equivalent organ doses calculated with the Monte Carlo code, according to the
Biological Effects of Ionizing Radiation (BEIR) empirical risk models. Years of life lost
(YLL) and years of life affected (YLA) were determined with the same risk model.<sup><xref rid="EUV344C30" ref-type="bibr">30</xref></sup></p><p>Finally, starting from the YLL and YLA, a rough economic analysis has been performed
using the Health Technology Assessment.<sup><xref rid="EUV344C31" ref-type="bibr">31</xref></sup></p><p>The ED to the first operator was assessed from data collected by lithium&#x02013;fluoride
thermoluminescent dosimeters (TLD) positioned on chest. The cumulative dose was measured
over consecutive procedures to achieve better accuracy and avoid underestimation due to
the small exposure per procedure. Different dosimeter sets were used during ConvA and MFA
procedures. Dosimeters were replaced every 2 months.</p></sec><sec id="s2c"><title>Statistical analysis</title><p>Descriptive statistic has been reported as mean &#x000b1; standard deviation or median and
interquartile Q1&#x02013;Q3 range (iqr) for skewed distributions in the case of continuous
variables and as absolute frequencies and percentages in the case of categorical
variables. Between-groups comparison has been performed with the unpaired Student's
<italic>t</italic>-test, the Mann&#x02013;Whitney <italic>U</italic> test, or Fisher's exact
test. Statistical differences in ED and fluoroscopy time between groups were tested with
the independent Mann&#x02013;Whitney <italic>U</italic> test (95% confidence level). All tests are
two sided, and a <italic>P</italic>-value of &#x0003c;0.05 has been considered statistically
significant. All statistical analyses were performed with the SPSS 21.0 software.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>Patients' enrolment in the study is depicted in <italic>Figure&#x000a0;<xref ref-type="fig" rid="EUV344F2">2</xref></italic>. <fig id="EUV344F2" orientation="portrait" position="float"><label>Figure&#x000a0;2</label><caption><p>Study flowchart showing enrolment, randomization and follow-up of participants. In
two cases, the MFA procedure was shifted to a ConvA one because of first operator
change in one case and mapping system failure in the other one. Both these procedures
were included in the MFA group as an intention-to-treat analysis.</p></caption><graphic xlink:href="euv34402"/></fig></p><p>Of the 262 participants (110 males, mean age 35.8 &#x000b1; 10.4 years), 134 (51%) were assigned to
MFA group and 128 (49%) to ConvA group. The clinical characteristics of the two groups were
comparable (<italic>Table&#x000a0;<xref ref-type="table" rid="EUV344TB1">1</xref></italic>).
<table-wrap id="EUV344TB1" orientation="portrait" position="float"><label>Table&#x000a0;1</label><caption><p>Demographic characteristics</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">MFA<break/><italic>n</italic> = 134</th><th align="left" rowspan="1" colspan="1">ConvA<break/><italic>n</italic> = 128</th><th align="left" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Female, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">79 (59)</td><td rowspan="1" colspan="1">73 (57)</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">36.3 &#x000b1; 10.4</td><td rowspan="1" colspan="1">35.4 &#x000b1; 10.4</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">BMI</td><td rowspan="1" colspan="1">24.4 &#x000b1; 4.4</td><td rowspan="1" colspan="1">23.5 &#x000b1; 4.4</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Previous ablation, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">10 (8)</td><td rowspan="1" colspan="1">13 (10)</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">EPS, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">16 (12)</td><td rowspan="1" colspan="1">15 (12)</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">AVNRT, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">84 (63)</td><td rowspan="1" colspan="1">79 (62)</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Right AP, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">10 (8)</td><td rowspan="1" colspan="1">11 (9)</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">Left AP, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">11 (8)</td><td rowspan="1" colspan="1">14 (11)</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">AFl, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">10 (8)</td><td rowspan="1" colspan="1">6 (5)</td><td rowspan="1" colspan="1">ns</td></tr><tr><td rowspan="1" colspan="1">AT, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">3 (2)</td><td rowspan="1" colspan="1">3 (2)</td><td rowspan="1" colspan="1">ns</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>BMI, body mass index; EPS, electrophysiological study; AVNRT, atrioventricular node
re-entry tachycardia; AP, accessory pathway; AFl, atrial flutter; AT, atrial
tachycardia.</p></fn></table-wrap-foot></table-wrap></p><sec id="s3a"><title>Procedural features</title><p>Of the 262 enrolled patients, 231 (88%) underwent an ablation following the EP study.
<xref ref-type="supplementary-material" rid="sup1">Supplementary material online,
Results section and <italic>Table S2</italic>,</xref> summarizes procedural data.</p><p>A 99% acute success rate was achieved in both groups (<italic>P</italic> = ns) with a
complications rate of 1.1% (<italic>P</italic> = ns). The procedural complications were as
follows: one arteriovenous fistula solved by compression in MFA group and two first-degree
atrioventricular node blocks spontaneously solved in 48 h in ConvA group. The mean
follow-up time was 12 &#x000b1; 4 months, during which no procedure-related complication occurred.
Of the 231 patients who underwent an ablation, the long-term success rate was 97% in MFA
group and 94% in ConvA group (<italic>P</italic> = ns).</p></sec><sec id="s3b"><title>Fluoroscopy use and effective dose</title><p>Fluoroscopy time and patient ED were significantly lower in the MFA group (0 s, iqr 0&#x02013;12;
0 mSv, iqr 0&#x02013;0.08) when compared with ConvA group (859 s, iqr 545&#x02013;1346; 8.87 mSv, iqr
3.67&#x02013;22.01; <italic>P</italic> &#x0003c; 0.00001). Similar results were obtained when the
analyses were restricted to the 231 procedures that ended with an ablation.</p><p>In the MFA group, X-ray was not used at all throughout the procedure in 72% (96/134) of
cases.</p><p>
<italic>Table&#x000a0;<xref ref-type="table" rid="EUV344TB2">2</xref></italic> and <xref ref-type="supplementary-material" rid="sup1">Supplementary material online, Results
section,</xref> describe fluoroscopy data. <table-wrap id="EUV344TB2" orientation="portrait" position="float"><label>Table&#x000a0;2</label><caption><p>Ionizing radiation data</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">MFA</th><th align="left" rowspan="1" colspan="1">ConvA</th><th align="left" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">All patients (<italic>n</italic> = 262)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Fluoroscopy time (s)</td><td rowspan="1" colspan="1">0 [0&#x02013;12]</td><td rowspan="1" colspan="1">859 [545&#x02013;1346]</td><td rowspan="1" colspan="1">&#x0003c;0.00001</td></tr><tr><td rowspan="1" colspan="1">DAP (cGy cm<sup>2</sup>)</td><td rowspan="1" colspan="1">278 [80&#x02013;791]</td><td rowspan="1" colspan="1">2036 [854&#x02013;5297]</td><td rowspan="1" colspan="1">&#x0003c;0.00001</td></tr><tr><td rowspan="1" colspan="1">ED (mSv)</td><td rowspan="1" colspan="1">0 [0&#x02013;0.08]</td><td rowspan="1" colspan="1">8.87 [3.67&#x02013;22.01]</td><td rowspan="1" colspan="1">&#x0003c;0.00001</td></tr><tr><td rowspan="1" colspan="1">Extrapolated ED (mSv)</td><td rowspan="1" colspan="1">0 [0&#x02013;0]</td><td rowspan="1" colspan="1">3.96 [1.68&#x02013;10.54]</td><td rowspan="1" colspan="1">&#x0003c;0.00001</td></tr><tr><td rowspan="1" colspan="1">Fluoro on pelvic area, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">3/134 (2)</td><td rowspan="1" colspan="1">62/128 (48)</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><p>Extrapolated ED: ED extrapolated by the formula: mSv = DAP (Gy cm<sup>2</sup>) &#x000d7;
0.20.</p></fn><fn id="tblfn3"><p>ED, effective dose; DAP, dose-area product.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s3c"><title>Lifetime attributable cancer risk</title><p>LAR estimates are reported in <italic>Table&#x000a0;<xref ref-type="table" rid="EUV344TB3">3</xref></italic> and <xref ref-type="supplementary-material" rid="sup1">Supplementary material online, Results section and <italic>Tables
S3&#x02013;S8</italic></xref>. <table-wrap id="EUV344TB3" orientation="portrait" position="float"><label>Table&#x000a0;3</label><caption><p>Lifetime attributable risks</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">LAR</th><th align="left" rowspan="2" colspan="1">Age</th><th align="center" colspan="2" rowspan="1">MFA<hr/></th><th align="center" colspan="2" rowspan="1">ConvA<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">Man</th><th align="left" rowspan="1" colspan="1">Woman</th><th align="left" rowspan="1" colspan="1">Man</th><th align="left" rowspan="1" colspan="1">Woman</th></tr></thead><tbody><tr><td rowspan="4" colspan="1">Mortality</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">4.8 (2.5&#x02013;8.2)</td><td rowspan="1" colspan="1">6.1 (3.9&#x02013;9.2)</td><td rowspan="1" colspan="1">136 (82&#x02013;215)</td><td rowspan="1" colspan="1">186 (131&#x02013;265)</td></tr><tr><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">4.0 (1.8&#x02013;7.0)</td><td rowspan="1" colspan="1">4.7 (2.8&#x02013;7.4)</td><td rowspan="1" colspan="1">105 (59&#x02013;171)</td><td rowspan="1" colspan="1">138 (94&#x02013;200)</td></tr><tr><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">3.7 (1.6&#x02013;6.7)</td><td rowspan="1" colspan="1">4.2 (2.4&#x02013;6.7)</td><td rowspan="1" colspan="1">94 (51&#x02013;156)</td><td rowspan="1" colspan="1">119 (79&#x02013;175)</td></tr><tr><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">3.7 (1.5&#x02013;6.9)</td><td rowspan="1" colspan="1">4.1 (2.3&#x02013;6.7)</td><td rowspan="1" colspan="1">94 (49&#x02013;158)</td><td rowspan="1" colspan="1">115 (76&#x02013;171)</td></tr><tr><td rowspan="4" colspan="1">Incidence</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">11.0 (6.0&#x02013;18.6)</td><td rowspan="1" colspan="1">15.4 (9.9&#x02013;25.3)</td><td rowspan="1" colspan="1">321 (198&#x02013;512)</td><td rowspan="1" colspan="1">486 (333&#x02013;773)</td></tr><tr><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">8.4 (4.3&#x02013;14.4)</td><td rowspan="1" colspan="1">10.9 (6.9&#x02013;17.4)</td><td rowspan="1" colspan="1">236 (140&#x02013;377)</td><td rowspan="1" colspan="1">335 (230&#x02013;509)</td></tr><tr><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">7.4 (3.6&#x02013;12.9)</td><td rowspan="1" colspan="1">8.9 (5.5&#x02013;14.0)</td><td rowspan="1" colspan="1">201 (117&#x02013;324)</td><td rowspan="1" colspan="1">267 (183&#x02013;393)</td></tr><tr><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">7.3 (3.4&#x02013;12.8)</td><td rowspan="1" colspan="1">8.2 (5.0&#x02013;12.8)</td><td rowspan="1" colspan="1">195 (111&#x02013;315)</td><td rowspan="1" colspan="1">241 (165&#x02013;350)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn4"><p>Lifetime attributable risks of all cancers mortality and incidence, calculated
according to BEIR risk models, with 95% confidence intervals from MFA
(<italic>N</italic> = 134) and ConvA procedures (<italic>N</italic> = 128) in
function of age at exposure and sex (number of cases in 100.000).</p></fn></table-wrap-foot></table-wrap></p><p>The risks of cancer incidence and mortality from a MFA procedure were reduced by 96%
compared with ConvA procedure. As expected, all risks decreased with aging and were always
higher for female patients at the same age of intervention.</p><p>Furthermore, a dramatic reduction has been calculated in YLL and YLA in MFA group in
comparison with ConvA group (<italic>Table&#x000a0;<xref ref-type="table" rid="EUV344TB4">4</xref></italic>). Undergoing a ConvA EP procedure at 35 years of age results in
almost 1 week of &#x02018;life-lost&#x02019; and in about 2 weeks of &#x02018;life-affected&#x02019; per patient, in
contrast with 5 h and half a day, respectively, with the MFA approach. <table-wrap id="EUV344TB4" orientation="portrait" position="float"><label>Table&#x000a0;4</label><caption><p>Years of life lost and years of life affected</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" rowspan="2" colspan="1">Age</th><th align="center" colspan="2" rowspan="1">MFA<hr/></th><th align="center" colspan="2" rowspan="1">ConvA<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">Man</th><th align="left" rowspan="1" colspan="1">Woman</th><th align="left" rowspan="1" colspan="1">Man</th><th align="left" rowspan="1" colspan="1">Woman</th></tr></thead><tbody><tr><td rowspan="4" colspan="1">YLL</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">0.00088 (0.00038&#x02013;0.0016)</td><td rowspan="1" colspan="1">0.00112 (0.00065&#x02013;0.00180)</td><td rowspan="1" colspan="1">0.023 (0.012&#x02013;0.038)</td><td rowspan="1" colspan="1">0.032 (0.022&#x02013;0.048)</td></tr><tr><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">0.00061 (0.00026&#x02013;0.00112)</td><td rowspan="1" colspan="1">0.00079 (0.00046&#x02013;0.00127)</td><td rowspan="1" colspan="1">0.016 (0.008&#x02013;0.026)</td><td rowspan="1" colspan="1">0.023 (0.015&#x02013;0.033)</td></tr><tr><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">0.00052 (0.00022&#x02013;0.00095)</td><td rowspan="1" colspan="1">0.00065 (0.00037&#x02013;0.00105)</td><td rowspan="1" colspan="1">0.013 (0.007&#x02013;0.022)</td><td rowspan="1" colspan="1">0.018 (0.012&#x02013;0.027)</td></tr><tr><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">0.00049 (0.00019&#x02013;0.00090)</td><td rowspan="1" colspan="1">0.00059 (0.00033&#x02013;0.00097)</td><td rowspan="1" colspan="1">0.012 (0.006&#x02013;0.020)</td><td rowspan="1" colspan="1">0.017 (0.011&#x02013;0.025)</td></tr><tr><td rowspan="4" colspan="1">YLA</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">0.0023 (0.0011&#x02013;0.0042)</td><td rowspan="1" colspan="1">0.0037 (0.0022&#x02013;0.0065)</td><td rowspan="1" colspan="1">0.063 (0.035&#x02013;0.106)</td><td rowspan="1" colspan="1">0.113 (0.073&#x02013;0.192)</td></tr><tr><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">0.0015 (0.0007&#x02013;0.0027)</td><td rowspan="1" colspan="1">0.0023 (0.0014&#x02013;0.0039)</td><td rowspan="1" colspan="1">0.042 (0.024&#x02013;0.068)</td><td rowspan="1" colspan="1">0.071 (0.048&#x02013;0.112)</td></tr><tr><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">0.0012 (0.0006&#x02013;0.0021)</td><td rowspan="1" colspan="1">0.0017 (0.0010&#x02013;0.0027)</td><td rowspan="1" colspan="1">0.032 (0.018&#x02013;0.053)</td><td rowspan="1" colspan="1">0.051 (0.035&#x02013;0.076)</td></tr><tr><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">0.0011 (0.0005&#x02013;0.0019)</td><td rowspan="1" colspan="1">0.0014 (0.0008&#x02013;0.0022)</td><td rowspan="1" colspan="1">0.029 (0.016&#x02013;0.047)</td><td rowspan="1" colspan="1">0.040 (0.027&#x02013;0.059)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn5"><p>Years of life lost and YLA with 95% confidence intervals from MFA
(<italic>N</italic> = 134) and ConvA procedures (<italic>N</italic> = 128) in
function of age at exposure and sex. Years of life lost are estimated subtracting
the effective years of life lived from the life expectancy for every patient who
dies from cancer according to the LAR calculation and dividing it by the number of
subjects who underwent the procedure. It results in an estimation of YLL per
patient. For example, performing a ConvA procedure on a woman aged 15 years means
that this woman will live 11.68 days (0.032&#x000d7;365 days/year) less than expected.
Translating it into a population of 1000 women aged 15 years, it means that the
procedures would account for a total of 32 YLL (0.032&#x000d7;1000 subjects).</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s3d"><title>Economic considerations</title><p>The significant reduction in YLL and YLA observed with the MFA could also be seen as an
increase in life expectancy and in the period of life without cancer. Assuming that the
period of life with cancer halves optimal quality of life, it can be derived that each
patient gains 2 adjusted quality of life weeks, e.g. 0.0348 quality-adjusted life years.
Using a range for the cost-effectiveness threshold between 30 000 and 50 000 as suggested
in some jurisdictions,<sup><xref rid="EUV344C32" ref-type="bibr">32</xref></sup> the
intervention would be affordable for an additional net cost ranging between &#x020ac;1151 and
&#x020ac;1918. This cost is approximately equivalent to the extra cost deriving from the
electroanatomic mapping system.</p></sec><sec id="s3e"><title>Ionizing radiation risk for electrophysiology physicians</title><p>For EP physicians, the estimated cumulative EDs were calculated taking into account the
shielding correction for using the protective apron and the thyroid collar and were
obtained from the data collected by a total number of 213 procedures (113 MFA&#x000a0;and 100
ConvA groups). As for patients, the ED was significantly lower in MFA group (1.55 &#x000b5;Sv per
procedure) in comparison with ConvA group (25.33 &#x000b5;Sv per procedure; <italic>P</italic>
&#x0003c; 0.001).</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><sec id="s4a"><title>Main findings of the study</title><p>This is the first prospective multicentre randomized study comparing conventional
fluoroscopy-guided procedures with procedures performed using the electroanatomical
mapping system as the primary catheter visualization tool in patients undergoing EP study
for SVTs. The results confirm safety and efficacy of a MFA in the ablation of a wide range
of SVTs. Notably, this randomized study shows that MFA allows a significant reduction in
patient's exposure and a decrease in the estimated risks of cancer incidence and mortality
and of YLA and YLL. Of course, the choice of MFA also affects the ionizing radiation
exposure of the medical staff.</p><p>Obviously, MFA involves a greater expense, but the benefits deriving from it are offset
in terms of cancer prevention strategy, and, based on our data, the increase in life
expectancy makes it economically affordable in most European countries.</p></sec><sec id="s4b"><title>Radiological exposure and risks</title><p>Medical radiological exposure and risks are topical and emerging issues of last year
literature.<sup><xref rid="EUV344C33" ref-type="bibr">33</xref>&#x02013;<xref rid="EUV344C36" ref-type="bibr">36</xref></sup> Cardiologists are responsible for &#x0223c;40% of the entire
ED from all medical sources, as a consequence of new capabilities and widespread
availability of new imaging techniques that require X-rays.<sup><xref rid="EUV344C37" ref-type="bibr">37</xref></sup> Radiation exposure involves patients and operators,
resulting in a non-negligible health risk for both.</p><p>A cornerstone to enhance radiation safety is optimization, i.e. reducing as much as
possible the use of X-rays for a given technique.<sup><xref rid="EUV344C26" ref-type="bibr">26</xref></sup> Techniques that allow high-quality imaging with lower
radiation exposure should therefore be used when available.</p><p>In our study, we showed that the use of one of these techniques
(EnSite<sup>TM</sup>NavX<sup>TM</sup> system) is effective in reducing radiation
exposure during EP procedures, with an identical success rate and without significantly
increasing procedural time.</p><p>Considering that X-rays are proven carcinogens (Class 1), the significant increase in the
cumulative exposure of patients and population is likely to cause an increased incidence
of cancer, with an important yet potentially avoidable public health threat.<sup><xref rid="EUV344C27" ref-type="bibr">27</xref></sup> This is the only published study that
estimates the lifetime attributable cancer risk of radiation with the Monte Carlo code.
The use of MFA reduced LAR by 96%, particularly in the youngest patients and in women.
Also YLL and YLA were significantly reduced in the MFA group. The difference between
median EDs calculated with the Monte Carlo code and with the international
formula<sup><xref rid="EUV344C31" ref-type="bibr">31</xref></sup> is probably due to
the characteristics of our study population, which is mainly constituted by young and
female patients. The advantage of the use of the electroanatomic system was in any case
statistically significant.</p><p>Reduction in radiation exposure during medical procedures is crucial also for the medical
staff. The occupational radiation exposure of cardiac electrophysiologists is two to three
times higher than that of diagnostic radiologists.<sup><xref rid="EUV344C27" ref-type="bibr">27</xref></sup> Cardiac use of fluoroscopy almost never reaches the
threshold for deterministic radiation injury, but it gives an additional lifetime risk of
fatal and non-fatal cancers ranging from 1/10 000 to 1/1000 that we should not
underestimate. In our study, we confirmed that performing MFA ablation of SVTs
significantly reduces professional exposure.</p></sec><sec id="s4c"><title>Economic considerations</title><p>The Health Technology Assessment evaluates medical technologies under clinical, ethical,
organizational, and economic points of view to assess if they are worth being
funded.<sup><xref rid="EUV344C38" ref-type="bibr">38</xref>,<xref rid="EUV344C39" ref-type="bibr">39</xref></sup></p><p>The MFA clearly produces clinical benefits for both patients and medical staff as it
decreases the risk of cancer due to radiation exposure. It may be argued that avoiding
patients' risks for unrelated diseases and protecting medical staff in its professional
environment deserve a higher priority. From a strictly economic perspective, the crucial
issue is whether MFA in ablation is affordable given the constraints in available
resources. This study does not provide enough data to conduct a cost-effectiveness
analysis, but it gives robust evidence in terms of increase in life expectancy and in
period of life free from cancer. This means that MFA procedures might be considered
economically affordable in most European countries.</p></sec><sec id="s4d"><title>Procedural features</title><p>Considering technical and procedural aspects, the 3D electroanatomic system shows
advantages not only as an efficient navigation system but also as a mapping system, thus
reducing X-ray exposure.</p><p>For example, a precise definition of the anatomy of the triangle of Koch and of the His
bundle (which is visualized as an area rather than just a point) facilitates
atrioventricular node re-entry tachycardia (AVNRT) ablation and avoids the need for
continuously monitoring with fluoroscopy the exact position of the node. Furthermore, the
3D electroanatomic system overcomes the difficulties deriving from the disappearance of
pre-excitation after the initial radiofrequency pulses, and it makes it easier to
accurately re-localize the accessory pathway (AP), thus avoiding time- and
radiation-consuming electrophysiological manoeuvres. Moreover, thanks to the possibility
of creating an activation map, it permits to eventually localize the gap in case of an
incomplete line during atrial flutter ablation. Finally, it allows greater catheter
stability in every kind of procedures, as demonstrated by fewer but longer radiofrequency
pulses observed in our MFA group.</p><p>As a consequence of all these advantages, we believe that specific training in the
&#x02018;minimal fluoroscopic approach&#x02019; should be part of every EP education programme.</p></sec><sec id="s4e"><title>Study limitations</title><p>The main limitation of our study is that the relationship between the ED and its lifetime
attributable risk was developed according to internationally accepted empirical risk
models,<sup><xref rid="EUV344C29" ref-type="bibr">29</xref></sup> and it could be
criticized that these models are not recommended for estimating risks in individual
patients. Nevertheless, it must be emphasized that no epidemiological study exists about
low levels of ionizing radiation and we regret that no biomarkers of acute ionizing
radiation injury were investigated.</p><p>We acknowledge that we did not perform an analysis about the dose for allied
professionals involved in the procedures and that we did not estimate the lifetime risks
for operators and allied professionals. These matters should be properly evaluated by a
specifically designed trial.</p><p>Furthermore, both ConvA and MFA procedures were performed differently in various EP labs
(i.e. numbers of diagnostic catheters, strategy in ablating left APs, etc.), but in the
study protocol, we intentionally decided to allow the operators working as routinary as
possible to have a better snapshot of MFA in everyday live EP labs.</p><p>Finally, a more exhaustive cost-effectiveness analysis would be desirable. The economic
observations reported suggest a first point of reference about the additional costs for
which the undiscounted gain benefits for patients might be considered affordable in
European countries, although crucial elements that may largely affect the overall value
for money are missing.</p></sec></sec><sec sec-type="conclusions" id="s5"><title>Conclusion</title><p>The NO-PARTY study is the first multicentre randomized controlled trial confirming that MFA
in SVTs ablation results in a clinically significant reduction in exposure to ionizing
radiation for both patient and operator. Notably, the reduction in patients' exposure
achieves a dramatic reduction in the estimated risks of cancer incidence and mortality and
in YLA and YLL. The increase in life expectancy and in the period of cancer-free life makes
the MFA economically affordable at a rough economical analysis. Thus, faced with such an
advantage in terms of cancer prevention, it would be desirable that MFA procedures were
increasingly performed, at least in young patients.</p></sec><sec id="s6"><title>Supplementary material</title><p>
<xref ref-type="supplementary-material" rid="sup1">Supplementary material is available at
<italic>Europace</italic> online.</xref>
</p></sec><sec id="s7"><title>Funding</title><p>The NO-PARTY was an independent study. St. Jude Medical, Italy, provided a research grant
conditioned to the e-CRF creation and the dosimeters management, provided technical support,
and supervised the implementation of the study, but it had no access to the database and did
not participate in the analysis of the results or in writing of the manuscript. Funding to
pay the Open Access publication charges for this article was provided by St. Jude
Medical.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sup1"><label>Supplementary Data</label><media xlink:href="euv344_supplementary_data.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>The authors thank Engineers: Roberta Annibali, Federico Borselli, Michele Ciani, Pasquale
De Juliis, Silvia Gilardone, Flavia Giovannetti, Stefano Indiani, Claudia Licciardello,
Fabio Lissa, and Anna Tranquilli (St. Jude Medical, Italy) for their expert technical
support. We also thank Dr Viviana Biagioli for editorial assistance. Finally, we wish to
thank Irene Colangelo, Antonio Mininno, Rosanna Poggi, and Enrico Romano.</p><p>
<bold>Conflict of interest:</bold> C.T. has served as member of the advisory board of
Biosense-Webster and has been consultant for St. Jude Medical. A.N. has received
compensation for belonging to the speakers&#x02019; bureau for St. Jude Medical, Boston Scientific,
Medtronic, and Biosense-Webster and has received a research grant from St. Jude Medical.
A.N. is consultant for Biosense-Webster. L.D.B. is consultant for Hansen Medical,
Biosense-Webster, and St. Jude Medical. L.D.B. has received speaker honoraria from
Biotronik, EPI-EP, and Atricure. G.F. has received compensation from St. Jude and Medtronic.
Other authors declare no relationships with industry.</p></ack><ref-list><title>References</title><ref id="EUV344C1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Picano</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Va&#x000f1;o</surname><given-names>E</given-names></name></person-group>
<article-title>The radiation issue in cardiology: the time for action is
now</article-title>. <source><italic>Cardiovasc
Ultrasound</italic></source><year>2011</year>;<volume>9</volume>:<fpage>35</fpage>.<pub-id pub-id-type="pmid">22104562</pub-id></mixed-citation></ref><ref id="EUV344C2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Va&#x000f1;o</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Gonzales</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Guibelalde</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Fernandez</surname><given-names>JM</given-names></name>,
<name name-style="western"><surname>Ten</surname><given-names>JI</given-names></name></person-group>
<article-title>Radiation exposure to medical staff in interventional and cardiac
radiology</article-title>. <source><italic>Br J
Radiol</italic></source><year>1998</year>;<volume>71</volume>:<fpage>793</fpage>&#x02013;<lpage>808</lpage>.</mixed-citation></ref><ref id="EUV344C3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Linet</surname><given-names>MS</given-names></name>,
<name name-style="western"><surname>Kim</surname><given-names>KP</given-names></name>,
<name name-style="western"><surname>Miller</surname><given-names>DL</given-names></name>,
<name name-style="western"><surname>Kleinerman</surname><given-names>RA</given-names></name>,
<name name-style="western"><surname>Simon</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Berrington de
Gonzalez</surname><given-names>A</given-names></name></person-group>
<article-title>Historical review of occupational exposures and cancer risks in medical
radiation workers</article-title>. <source><italic>Radiat
Res</italic></source><year>2010</year>;<volume>174</volume>:<fpage>793</fpage>&#x02013;<lpage>808</lpage>.<pub-id pub-id-type="pmid">21128805</pub-id></mixed-citation></ref><ref id="EUV344C4"><label>4</label><mixed-citation publication-type="book">
<collab>Committee to Assess Health Risks from Exposure to Low Levels of Ionizing
Radiation; Nuclear and Radiation Studies Board, Division on Earth and Life Studies,
National Research Council of the National Academies</collab>. <source><italic>Health
Risks From Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase
2</italic></source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>The
National Academies Press</publisher-name>; <year>2006</year>.</mixed-citation></ref><ref id="EUV344C5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Papagiannis</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Tsoutsinos</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Kirvassilis</surname><given-names>G</given-names></name>,
<name name-style="western"><surname>Sofianidou</surname><given-names>I</given-names></name>,
<name name-style="western"><surname>Koussi</surname><given-names>T</given-names></name>,
<name name-style="western"><surname>Laskari</surname><given-names>C</given-names></name><etal>et
al</etal></person-group>
<article-title>Nonfluoroscopic catheter navigation for
radiofrequency catheter ablation of supraventricular tachycardia in
children</article-title>. <source><italic>Pacing Clin
Electrophysiol</italic></source><year>2006</year>;<volume>29</volume>:<fpage>971</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">16981921</pub-id></mixed-citation></ref><ref id="EUV344C6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>G</given-names></name>,
<name name-style="western"><surname>Clark</surname><given-names>JM</given-names></name></person-group>
<article-title>Elimination of fluoroscopy use in a pediatric electrophysiology
laboratory utilizing three-dimensional mapping</article-title>. <source><italic>Pacing
Clin
Electrophysiol</italic></source><year>2007</year>;<volume>30</volume>:<fpage>510</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">17437575</pub-id></mixed-citation></ref><ref id="EUV344C7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Miyake</surname><given-names>CY</given-names></name>,
<name name-style="western"><surname>Mah</surname><given-names>DY</given-names></name>,
<name name-style="western"><surname>Atallah</surname><given-names>J</given-names></name></person-group>
<article-title>Nonfluroscopic imaging systems reduce radiation exposure in children
undergoing ablation of supraventricular tachycardia</article-title>.
<source><italic>Heart
Rhythm</italic></source><year>2011</year>;<volume>8</volume>:<fpage>519</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">21167315</pub-id></mixed-citation></ref><ref id="EUV344C8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Papagiannis</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Avramidis</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>Alexopoulos</surname><given-names>C</given-names></name>,
<name name-style="western"><surname>Kirvassilis</surname><given-names>G</given-names></name></person-group>
<article-title>Radiofrequency ablation of accessory pathways in children and congenital
heart disease patients: impact of a nonfluoroscopic navigation system</article-title>.
<source><italic>Pacing Clin
Electrophysiol</italic></source><year>2011</year>;<volume>34</volume>:<fpage>1288</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">21851369</pub-id></mixed-citation></ref><ref id="EUV344C9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kwong</surname><given-names>W</given-names></name>,
<name name-style="western"><surname>Neilson</surname><given-names>AL</given-names></name>,
<name name-style="western"><surname>Chiu</surname><given-names>CC</given-names></name>,
<name name-style="western"><surname>Gross</surname><given-names>GJ</given-names></name>,
<name name-style="western"><surname>Hamilton</surname><given-names>RM</given-names></name>,
<name name-style="western"><surname>Soucie</surname><given-names>L</given-names></name><etal>et
al</etal></person-group>
<article-title>The effect of NavX on fluoroscopy times in
pediatric catheter ablation</article-title>. <source><italic>J Interv Card
Electrophysiol</italic></source><year>2012</year>;<volume>33</volume>:<fpage>123</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">22006437</pub-id></mixed-citation></ref><ref id="EUV344C10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Casella</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dello
Russo</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Fassini</surname><given-names>G</given-names></name>,
<name name-style="western"><surname>Andreini</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>De Iuliis</surname><given-names>P</given-names></name>,
<name name-style="western"><surname>Mushtaq</surname><given-names>S</given-names></name><etal>et
al</etal></person-group>
<article-title>Manifold benefits of choosing a minimally
fluoroscopic catheter ablation approach</article-title>. <source><italic>World J
Cardiol</italic></source><year>2013</year>;<volume>5</volume>:<fpage>8</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">23538845</pub-id></mixed-citation></ref><ref id="EUV344C11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Scaglione</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Ebrille</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Caponi</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>Blandino</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Di Donna</surname><given-names>P</given-names></name>,
<name name-style="western"><surname>Siboldi</surname><given-names>A</given-names></name><etal>et
al</etal></person-group>
<article-title>Single center experience of fluoroless AVNRT
ablation guided by electroanatomic reconstruction in children and
adolescents</article-title>. <source><italic>Pacing Clin
Electrophysiol</italic></source><year>2013</year>;<volume>36</volume>:<fpage>1460</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">23713835</pub-id></mixed-citation></ref><ref id="EUV344C12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mah</surname><given-names>DY</given-names></name>,
<name name-style="western"><surname>Miyake</surname><given-names>CY</given-names></name>,
<name name-style="western"><surname>Sherwin</surname><given-names>ED</given-names></name>,
<name name-style="western"><surname>Walsh</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Anderson</surname><given-names>MJ</given-names></name>,
<name name-style="western"><surname>Western</surname><given-names>K</given-names></name><etal>et
al</etal></person-group>
<article-title>The use of an integrated electroanatomic
mapping system and intracardiac echocardiography to reduce radiation exposure in
children and young adults undergoing ablation of supraventricular
tachycardia</article-title>.
<source><italic>Europace</italic></source><year>2014</year>;<volume>16</volume>:<fpage>277</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">23928735</pub-id></mixed-citation></ref><ref id="EUV344C13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Earley</surname><given-names>MJ</given-names></name>,
<name name-style="western"><surname>Showkathali</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Alzetani</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Kistler</surname><given-names>PM</given-names></name>,
<name name-style="western"><surname>Gupta</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>Abrams</surname><given-names>DJ</given-names></name><etal>et
al</etal></person-group>
<article-title>Radiofrequency abaltion of arrhythmias guided
by non-fluoroscopic catheter location: a prospective randomized trial</article-title>.
<source><italic>Eur Heart
J</italic></source><year>2006</year>;<volume>27</volume>:<fpage>1223</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">16613932</pub-id></mixed-citation></ref><ref id="EUV344C14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tuzcu</surname><given-names>V</given-names></name></person-group>
<article-title>A nonfluoroscopic approach for electrophysiology and
catheter ablation procedures using a three-dimensional navigation
system</article-title>. <source><italic>Pacing Clin
Electrophysiol</italic></source><year>2007</year>;<volume>30</volume>:<fpage>519</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">17437576</pub-id></mixed-citation></ref><ref id="EUV344C15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Alvarez</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Tercedor</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Almansa</surname><given-names>I</given-names></name>,
<name name-style="western"><surname>Ros</surname><given-names>N</given-names></name>,
<name name-style="western"><surname>Galdeano</surname><given-names>RS</given-names></name>,
<name name-style="western"><surname>Burillo</surname><given-names>F</given-names></name><etal>et
al</etal></person-group>
<article-title>Safety and feasibility of catheter ablation
for atrioventricular nodal re-entrant tachycardia without fluoroscopic
guidance</article-title>. <source><italic>Heart
Rhythm</italic></source><year>2009</year>;<volume>6</volume>:<fpage>1714</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">19959117</pub-id></mixed-citation></ref><ref id="EUV344C16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Alvarez</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Tercedor</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Herrera</surname><given-names>N</given-names></name>,
<name name-style="western"><surname>Mu&#x000f1;oz</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Galdeano</surname><given-names>RS</given-names></name>,
<name name-style="western"><surname>Valverde</surname><given-names>F</given-names></name><etal>et
al</etal></person-group>
<article-title>Cavotricuspid isthmus catheter ablation
without the use of fluoroscopy as a first-line treatment</article-title>.
<source><italic>J Cardiovasc
Electrophysiol</italic></source><year>2011</year>;<volume>22</volume>:<fpage>656</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">21114703</pub-id></mixed-citation></ref><ref id="EUV344C17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Casella</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Pelargonio</surname><given-names>G</given-names></name>,
<name name-style="western"><surname>Dello
Russo</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Riva</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Bartoletti</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Santangeli</surname><given-names>P</given-names></name><etal>et
al</etal></person-group>
<article-title>&#x0201c;Near-zero&#x0201d; fluoroscopic exposure in
supraventricular arrhythmia ablation using the EnSite NavX<sup>TM</sup> mapping system:
personal experience and review of the literature</article-title>. <source><italic>J
Interv Card
Electrophysiol</italic></source><year>2011</year>;<volume>31</volume>:<fpage>109</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="pmid">21365263</pub-id></mixed-citation></ref><ref id="EUV344C18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fernandez-Gomez</surname><given-names>JM</given-names></name>,
<name name-style="western"><surname>Mori&#x000f1;a-Vazquez</surname><given-names>P</given-names></name>,
<name name-style="western"><surname>Del Rio
Morales</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Venegas-Gamero</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Barba-Pichardo</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Herrera
Carranza</surname><given-names>M</given-names></name></person-group>
<article-title>Exclusion of fluoroscopy use in catheter ablation procedures: six years
of experience at a single center</article-title>. <source><italic>J Cardiovasc
Electrophysiol</italic></source><year>2014</year>;<volume>25</volume>:<fpage>638</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">24611978</pub-id></mixed-citation></ref><ref id="EUV344C19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Schoene</surname><given-names>K</given-names></name>,
<name name-style="western"><surname>Rolf</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Schloma</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>John</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Arya</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Dinov</surname><given-names>B</given-names></name><etal>et
al</etal></person-group>
<article-title>Ablation of typical atrial flutter using a
non-fluoroscopic catheter tracking system vs. conventional fluoroscopy&#x02013;results from a
prospective randomized study</article-title>.
<source><italic>Europace</italic></source><year>2015</year>;<volume>17</volume>:<fpage>1117</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">25736724</pub-id></mixed-citation></ref><ref id="EUV344C20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Christoph</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Wunderlich</surname><given-names>C</given-names></name>,
<name name-style="western"><surname>Moebius</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Forkmann</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Sitzy</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Salmas</surname><given-names>J</given-names></name><etal>et
al</etal></person-group>
<article-title>Fluoroscopy integrated 3D mapping
significantly reduces radiation exposure during ablation for a wide spectrum of cardiac
arrhythmias</article-title>.
<source><italic>Europace</italic></source><year>2015</year>;<volume>17</volume>:<fpage>928</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">25609207</pub-id></mixed-citation></ref><ref id="EUV344C21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Stabile</surname><given-names>G</given-names></name>,
<name name-style="western"><surname>Scaglione</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>del Greco</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>De Ponti</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Bongiorni</surname><given-names>MG</given-names></name>,
<name name-style="western"><surname>Zoppo</surname><given-names>F</given-names></name><etal>et
al</etal></person-group>
<article-title>Reduced fluoroscopy exposure during ablation
of atrial fibrillation using a novel electroanatomical navigation system: a multicentre
experience</article-title>.
<source><italic>Europace</italic></source><year>2012</year>;<volume>14</volume>:<fpage>60</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">21893511</pub-id></mixed-citation></ref><ref id="EUV344C22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Casella</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dello
Russo</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Pelargonio</surname><given-names>G</given-names></name>,
<name name-style="western"><surname>Bongiorni</surname><given-names>MG</given-names></name>,
<name name-style="western"><surname>Del Greco</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Piacenti</surname><given-names>M</given-names></name><etal>et
al</etal></person-group>
<article-title>Rationale and design of the NO-PARTY trial:
near-zero fluoroscopic exposure during catheter ablation of supraventricular arrhythmias
in young patients</article-title>. <source><italic>Cardiol
Young</italic></source><year>2012</year>;<volume>22</volume>:<fpage>539</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">22325367</pub-id></mixed-citation></ref><ref id="EUV344C23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ventura</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Rostock</surname><given-names>T</given-names></name>,
<name name-style="western"><surname>Klemm</surname><given-names>HU</given-names></name>,
<name name-style="western"><surname>Lutomsky</surname><given-names>B</given-names></name>,
<name name-style="western"><surname>Demir</surname><given-names>C</given-names></name>,
<name name-style="western"><surname>Weiss</surname><given-names>C</given-names></name><etal>et
al</etal></person-group>
<article-title>Catheter ablation of common-type atrial
flutter guided by three-dimensional right atrial geometry reconstruction and catheter
tracking use cutaneous patches: a randomized prospective study</article-title>.
<source><italic>J Cardiovasc
Electrophysiol</italic></source><year>2004</year>;<volume>15</volume>:<fpage>1157</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">15485440</pub-id></mixed-citation></ref><ref id="EUV344C24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Krum</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>Goel</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Hauck</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Schweitzer</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Hare</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Attari</surname><given-names>M</given-names></name><etal>et
al</etal></person-group>
<article-title>Catheter location, tracking, cardiac chamber
geometry creation, and ablation using cutaneous patches</article-title>.
<source><italic>J Interv Cardiac
Electrophysiol</italic></source><year>2005</year>;<volume>12</volume>:<fpage>17</fpage>&#x02013;<lpage>22</lpage>.</mixed-citation></ref><ref id="EUV344C25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rotter</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Takahashi</surname><given-names>Y</given-names></name>,
<name name-style="western"><surname>Sanders</surname><given-names>P</given-names></name>,
<name name-style="western"><surname>Haissaguerre</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Li-Fern
Hsu</surname><given-names>PJ</given-names></name>,
<name name-style="western"><surname>Sacher</surname><given-names>F</given-names></name><etal>et
al</etal></person-group>
<article-title>Reduction of fluoroscopy exposure and
procedure duration during ablation of atrial fibrillation using a novel anatomical
navigation system</article-title>. <source><italic>Eur Heart
J</italic></source><year>2005</year>;<volume>26</volume>:<fpage>1415</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">15741228</pub-id></mixed-citation></ref><ref id="EUV344C26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Estner</surname><given-names>HL</given-names></name>,
<name name-style="western"><surname>Deisenhofer</surname><given-names>I</given-names></name>,
<name name-style="western"><surname>Luik</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Ndrepepa</surname><given-names>G</given-names></name>,
<name name-style="western"><surname>von Bary</surname><given-names>C</given-names></name>,
<name name-style="western"><surname>Zrenner</surname><given-names>B</given-names></name><etal>et
al</etal></person-group>
<article-title>Electrical isolation of pulmonary veins in
patients with atrial fibrillation: reduction of fluoroscopy exposure and procedure
duration by the use of a non-fluoroscopic navigation system (NavX&#x000ae;)</article-title>.
<source><italic>Europace</italic></source><year>2006</year>;<volume>8</volume>:<fpage>583</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">16831837</pub-id></mixed-citation></ref><ref id="EUV344C27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Birch</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Marshall</surname><given-names>M</given-names></name></person-group>
<article-title>Computation of bremsstrahlung x-ray spectra and comparison with spectra
measured with a Ge(Li) detector</article-title>. <source><italic>Phys Med
Biol</italic></source><year>1979</year>;<volume>24</volume>:<fpage>505</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">461510</pub-id></mixed-citation></ref><ref id="EUV344C28"><label>28</label><mixed-citation publication-type="journal">
<collab>International Commission on Radiological Protection</collab>. <article-title>ICRP
Publication 103, the 2007 Recommendation of the International Commission on Radiological
Protection</article-title>. <source><italic>Ann
ICRP</italic></source><year>2007</year>;<volume>37</volume>:<fpage>60</fpage>&#x02013;<lpage>318</lpage>.</mixed-citation></ref><ref id="EUV344C29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Heidbuchel</surname><given-names>H</given-names></name>,
<name name-style="western"><surname>Wittkampf</surname><given-names>FHM</given-names></name>,
<name name-style="western"><surname>Vano</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Ernst</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Schilling</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Picano</surname><given-names>E</given-names></name><etal>et
al</etal></person-group>
<article-title>Practical ways to reduce radiation dose for
patients and staff during device implantations and electrophysiological
procedures</article-title>.
<source><italic>Europace</italic></source><year>2014</year>;<volume>16</volume>:<fpage>946</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">24792380</pub-id></mixed-citation></ref><ref id="EUV344C30"><label>30</label><mixed-citation publication-type="other">
<comment>Surveillance, Epidemiology, and End Results (SEER) Program (<uri xlink:href="www.seer.cancer.gov">www.seer.cancer.gov</uri>) SEER*Stat Database:
Incidence - SEER 9 Regs Research Data, Nov 2014 Sub (1973&#x02013;2012) - Linked To County
Attributes - Total U.S., 1969&#x02013;2013 Counties, National Cancer Institute, DCCPS,
Surveillance Research Program, Surveillance Systems Branch, released April 2015, based
on the November 2014 submission</comment>.</mixed-citation></ref><ref id="EUV344C31"><label>31</label><mixed-citation publication-type="other">
<collab>International Network of Agencies for Health Technology Assessment
(INAHTA)</collab>. <comment><uri xlink:href="http://www.inahta.org/HTA">http://www.inahta.org/HTA</uri></comment>.</mixed-citation></ref><ref id="EUV344C32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Eichler</surname><given-names>HG</given-names></name>,
<name name-style="western"><surname>Kong</surname><given-names>SX</given-names></name>,
<name name-style="western"><surname>Gerth</surname><given-names>WC</given-names></name>,
<name name-style="western"><surname>Mavros</surname><given-names>P</given-names></name>,
<name name-style="western"><surname>J&#x000f6;nsson</surname><given-names>B</given-names></name></person-group>
<article-title>Use of cost-effectiveness analysis in health-care resource allocation
decision-making: how are cost-effectiveness thresholds expected to
emerge?</article-title><source><italic>Value
Health</italic></source><year>2004</year>;<volume>7</volume>:<fpage>518</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">15367247</pub-id></mixed-citation></ref><ref id="EUV344C33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fazel</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Gerber</surname><given-names>T</given-names></name>,
<name name-style="western"><surname>Balter</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Brenner</surname><given-names>DJ</given-names></name>,
<name name-style="western"><surname>Carr</surname><given-names>JJ</given-names></name>,
<name name-style="western"><surname>Cerqueira</surname><given-names>MD</given-names></name><etal>et
al</etal></person-group>
<collab>on behalf of the American Heart Association Council
on Quality of Care and Outcomes Research, Council on Clinical Cardiology, and Council on
Cardiovascular Radiology and Intervention</collab>. <article-title>Approaches to
enhancing radiation safety in cardiovascular imaging. A scientific statement from the
American Heart Association</article-title>.
<source><italic>Circulation</italic></source><year>2014</year>;<volume>130</volume>:<fpage>1730</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">25366837</pub-id></mixed-citation></ref><ref id="EUV344C34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Picano</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Va&#x000f1;o</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Rehani</surname><given-names>MM</given-names></name>,
<name name-style="western"><surname>Cuocolo</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Mont</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Bodi</surname><given-names>V</given-names></name><etal>et
al</etal></person-group>
<article-title>The appropriate and justified use of medical
radiation in cardiovascular imaging: a position document of the ESC Associations of
Cardiovascular Imaging, Percutaneous Cardiovascular Interventions and
Electrophysiology</article-title>. <source><italic>Eur Heart
J</italic></source><year>2014</year>;<volume>35</volume>:<fpage>665</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">24401558</pub-id></mixed-citation></ref><ref id="EUV344C35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Natarajan</surname><given-names>MK</given-names></name>,
<name name-style="western"><surname>Paul</surname><given-names>N</given-names></name>,
<name name-style="western"><surname>Mercuri</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Waller</surname><given-names>EJ</given-names></name>,
<name name-style="western"><surname>Leipsic</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Traboulsi</surname><given-names>M</given-names></name><etal>et
al</etal></person-group>
<article-title>Canadian Cardiovascular Society Position
Statement on radiation exposure from cardiac imaging and interventional
procedures</article-title>. <source><italic>Canadian J
Cardiol</italic></source><year>2013</year>;<volume>29</volume>:<fpage>1361</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="EUV344C36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Estner</surname><given-names>HL</given-names></name>,
<name name-style="western"><surname>Bongiorni</surname><given-names>MG</given-names></name>,
<name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Dagres</surname><given-names>N</given-names></name>,
<name name-style="western"><surname>Hernandez-Madrid</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Blomstr&#x000f6;m-Lundqvist</surname><given-names>C</given-names></name></person-group>
<article-title>Use of fluoroscopy in clinical electrophysiology in Europe: results of
the European Heart Rhythm Association Survey</article-title>.
<source><italic>Europace</italic></source><year>2015</year>;<volume>17</volume>:<fpage>1149</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">26116687</pub-id></mixed-citation></ref><ref id="EUV344C37"><label>37</label><mixed-citation publication-type="book">
<collab>National Council on Radiation Protection &#x00026; Measurements</collab>.
<article-title>Ionizing Radiation Exposure of the Population of the United
States</article-title>. <comment>NCRP Report No.160</comment>
<publisher-loc>Bethesda,
MD</publisher-loc>: <publisher-name>National Council on Radiation Protection &#x00026;
Measurements</publisher-name>;
<comment>March</comment><year>2009</year>.</mixed-citation></ref><ref id="EUV344C38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Henshall</surname><given-names>C</given-names></name>,
<name name-style="western"><surname>Mardhani-Bayne</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Fronsdal</surname><given-names>KB</given-names></name>,
<name name-style="western"><surname>Klemp</surname><given-names>M</given-names></name></person-group>
<article-title>Interactionsbetween health technology assessment, coverage, and
regulatory processes: emerging issues, goals, and opportunities</article-title>.
<source><italic>Int J Technol
Assess</italic></source><year>2011</year>;<volume>27</volume>:<fpage>253</fpage>&#x02013;<lpage>60</lpage>.</mixed-citation></ref><ref id="EUV344C39"><label>39</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Facey</surname><given-names>K</given-names></name></person-group>
<comment>Health Technology Assessment (HTA) glossary</comment>
<publisher-name>INAHTA&#x02013;International Network of Agencies for Health Technology
Assessment</publisher-name>; <year>2006</year>.</mixed-citation></ref></ref-list></back></article>